论文部分内容阅读
人与人之间传播Creuzfelat-Jakob病(CJD)90年代以来已成为临床事实。1997年12月法国已统计到的54例经尸检证实或临床诊断很可能的CJD病人,他们均接受过提取的生长激素(EGH)治疗且出现任何其他病因都不能解释这些患者的症状。 用EGH后的CJD的主要特征是发生在年轻病人(10～35岁)。早期征象(行走障碍、复视)令人想到的是最初诊断是后颅窝肿瘤或溶酶体病。经数月后出
Creuzfelat-Jakob disease (CJD) has spread from person to person since the 1990s. In December 1997, 54 CJD patients confirmed by autopsy or clinical diagnosis in France were enrolled. All of them had been treated with extracted growth hormone (EGH) and any other etiology could not explain the symptoms of these patients. The main characteristic of CJD after EGH is in young patients (10 to 35 years). Early signs (walking disorders, diplopia) It is conceivable that the initial diagnosis of posterior fossa tumors or lysosomal diseases. After a few months out